stockrow
Friday 6 November 2026
Export TEVA’s income statement to Excel — free account
Teva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
42.43
0.65
+1.56%
Follow TEVA
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
535.43 | 0.00 | 0.00 | 0.00 | 0.00 | 22.76 | 0.00 | 0.00 | 0.00 | 25.17 |
Piotroski F-Score |
3 | 3 | 5 | 5 | 5 | 7 | 4 | 6 | 5 | 8 |
Altman Z-Score |
0.86 | (0.40) | 0.44 | 0.25 | (0.05) | 0.34 | (0.05) | 0.17 | 0.40 | 0.79 |
P/S ratio |
1.63 | 0.68 | 0.86 | 0.63 | 0.63 | 0.60 | 0.71 | 0.75 | 1.51 | 2.07 |
P/FCF ratio |
5.66 | 3.16 | 5.86 | 18.89 | 14.99 | 17.43 | 9.53 | 13.12 | 31.47 | 30.23 |
Altman Z″-Score (non-manufacturers) |
1.18 | (1.70) | 0.15 | (0.10) | (0.91) | 0.06 | (0.95) | (0.67) | (0.97) | (0.41) |
Beneish M-Score |
(2.32) | (3.81) | (3.02) | (2.62) | (3.20) | (2.52) | (3.10) | (2.77) | (3.00) | (2.35) |
P/Operating CF |
25.12 | 17.74 | 42.90 | 19.87 | 31.92 | 20.90 | 10.87 | 10.08 | 43.35 | 30.86 |
Dividend Safety Score |
— | — | — | — | — | — | — | — | — | 52 |
P/B ratio |
1.14 | 1.01 | 1.00 | 0.71 | 0.96 | 0.85 | 1.23 | 1.47 | 4.63 | 4.52 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
3.22 | 2.09 | 2.35 | 2.11 | 2.06 | 1.92 | 1.94 | 1.80 | 2.38 | 2.84 |
EV/EBITDA |
19.20 | 0.00 | 13.27 | 27.87 | 0.00 | 9.99 | 0.00 | 18.00 | 19.36 | 15.50 |
EV/Operating CF |
13.51 | 21.01 | 17.53 | 47.63 | 28.21 | 38.11 | 18.23 | 20.87 | 31.60 | 29.71 |
EV/FCF |
11.16 | 9.68 | 15.97 | 62.94 | 48.66 | 55.59 | 26.12 | 31.37 | 49.76 | 41.44 |
Quick Ratio |
0.46 | 0.45 | 0.53 | 0.56 | 0.51 | 0.61 | 0.57 | 0.54 | 0.50 | 0.54 |
Current Ratio |
0.93 | 0.86 | 0.96 | 0.98 | 0.99 | 1.14 | 1.05 | 1.02 | 0.98 | 1.04 |
Net Debt/EBITDA |
9.46 | (2.05) | 8.40 | 19.51 | (11.79) | 6.86 | (20.71) | 10.47 | 7.11 | 4.19 |
Debt/Assets |
38.47% | 45.99% | 47.65% | 46.82% | 51.18% | 48.34% | 48.20% | 45.62% | 45.22% | 41.24% |
Debt/Equity |
1.02 | 1.73 | 1.83 | 1.79 | 2.34 | 2.05 | 2.47 | 2.44 | 3.31 | 2.12 |
Asset Turnover |
0.30 | 0.27 | 0.28 | 0.29 | 0.31 | 0.32 | 0.33 | 0.36 | 0.40 | 0.43 |
Operating CF/Net income |
76.84 | (0.13) | (1.02) | (0.75) | (0.30) | 1.91 | (0.65) | (2.45) | (0.76) | 1.17 |
Capex/Depreciation |
0.72 | 1.23 | 0.13 | (0.11) | (0.33) | (0.19) | (0.37) | (0.40) | (0.43) | (0.47) |
| 0.23% | (71.10%) | (15.52%) | (6.48%) | (30.55%) | 3.74% | (24.65%) | (6.69%) | (24.27%) | 21.21% | |
| 0.09% | (20.19%) | (3.65%) | (1.69%) | (7.38%) | 0.85% | (5.34%) | (1.28%) | (3.96%) | 3.52% | |
ROIC |
1.93% | (21.74%) | 2.02% | (0.69%) | (6.41%) | 3.34% | (5.08%) | 1.09% | 3.07% | 6.37% |
Return on Tangible Assets |
1.00% | (321.87%) | (37.84%) | (16.05%) | (65.02%) | 5.54% | (38.70%) | (9.34%) | (37.79%) | 30.85% |
Average Days of Receivables |
125.37 | 116.23 | 116.31 | 122.68 | 100.37 | 104.11 | 90.39 | 78.50 | 67.49 | 78.44 |
Research and Development Expense of Revenue |
9.64% | 7.94% | 6.64% | 5.98% | 5.98% | 6.09% | 5.61% | 6.01% | 6.03% | 5.87% |
Selling, General and Administrative Expense of Revenue |
23.49% | 21.65% | 23.06% | 22.54% | 22.04% | 22.22% | 23.08% | 22.07% | 22.38% | 23.02% |
Intangible Assets out of Total Assets |
0.71 | 0.65 | 0.64 | 0.63 | 0.58 | 0.58 | 0.54 | 0.52 | 0.50 | 0.49 |
Share Based Compensation of Revenue |
0.57% | 0.59% | 0.85% | 0.70% | 0.77% | 0.75% | 0.83% | 0.76% | 0.74% | 0.91% |
Graham Net Nets |
(1.14) | (2.39) | (1.98) | (2.71) | (2.51) | (2.50) | (2.21) | (1.92) | (0.86) | (0.53) |
Graham Number |
7.19 | 0.00 | 0.00 | 0.00 | 0.00 | 9.34 | 0.00 | 0.00 | 0.00 | 13.89 |
Earnings Yield |
0.19% | (108.40%) | (15.05%) | (9.39%) | (37.72%) | 4.39% | (22.25%) | (4.40%) | (6.58%) | 3.97% |
Free Cash Flow Yield |
17.67% | 31.68% | 17.05% | 5.29% | 6.67% | 5.74% | 10.49% | 7.62% | 3.18% | 3.31% |
Revenue per Share |
22.94 | 22.03 | 17.90 | 15.48 | 15.21 | 14.41 | 13.45 | 14.16 | 14.63 | 15.07 |
Operating CF per Share |
5.47 | 2.19 | 2.40 | 0.69 | 1.11 | 0.72 | 1.43 | 1.22 | 1.10 | 1.44 |
Capex per Share |
1.15 | 2.56 | 0.23 | (0.17) | (0.47) | (0.23) | (0.43) | (0.41) | (0.40) | (0.41) |
Free Cash Flow per Share |
6.62 | 4.75 | 2.63 | 0.52 | 0.64 | 0.50 | 1.00 | 0.81 | 0.70 | 1.03 |
Cash per Share |
1.03 | 0.95 | 1.75 | 1.81 | 1.99 | 1.96 | 2.52 | 2.88 | 2.92 | 3.11 |
Shareholders Equity per Share |
36.64 | 18.45 | 15.47 | 13.81 | 10.10 | 10.20 | 7.75 | 7.26 | 4.76 | 6.91 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
36.64 | 18.45 | 15.47 | 13.81 | 10.10 | 10.20 | 7.75 | 7.26 | 4.76 | 6.91 |
Free Cash Flow |
6,326.00 | 4,828.00 | 2,685.00 | 566.00 | 705.00 | 547.00 | 1,110.00 | 910.00 | 792.00 | 1,182.00 |
Working Capital |
(1,260.00) | (2,539.00) | (528.00) | (210.00) | (159.00) | 1,546.00 | 582.00 | 238.00 | (244.00) | 490.00 |
Capital Expenditures |
1,101.00 | 2,603.00 | 239.00 | (182.00) | (511.00) | (251.00) | (480.00) | (458.00) | (455.00) | (467.00) |
Net Current Asset Value |
(40,836.00) | (36,488.00) | (31,095.00) | (28,943.00) | (26,574.00) | (23,849.00) | (23,362.00) | (22,868.00) | (21,394.00) | (18,888.00) |
EV/EBIT |
32.78 | 0.00 | 30.85 | 0.00 | 0.00 | 17.73 | 0.00 | 65.93 | 40.34 | 22.70 |
Capex to Sales |
(0.05) | (0.12) | (0.01) | 0.01 | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 |
Price to Operating Income |
16.62 | 0.00 | 11.33 | 0.00 | 0.00 | 5.56 | 0.00 | 27.57 | 25.51 | 16.56 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.19 | 0.28 | 0.27 | 0.27 | 0.25 | 0.22 | 0.23 | 0.20 | 0.23 | 0.25 |
Cash ROIC |
8.81% | 9.25% | 5.78% | 1.29% | 1.80% | 1.50% | 3.40% | 2.92% | 2.99% | 4.18% |
Accounts Receivable Turnover |
3.40 | 3.06 | 2.82 | 2.94 | 3.25 | 3.49 | 3.63 | 4.46 | 5.12 | 5.10 |
Accounts Payable Turnover |
4.93 | 5.57 | 5.09 | 5.24 | 5.14 | 4.81 | 4.45 | 3.65 | 3.53 | 3.52 |
Inventory Turnover |
2.25 | 2.38 | 2.07 | 2.04 | 2.02 | 2.02 | 2.08 | 2.09 | 2.41 | 2.69 |
Average Days of Payables |
78.39 | 64.16 | 67.80 | 67.06 | 71.75 | 74.29 | 86.61 | 115.82 | 94.81 | 111.04 |
Days of Inventory on Hand |
180.03 | 152.70 | 173.11 | 172.61 | 179.91 | 168.22 | 175.94 | 178.98 | 129.41 | 139.46 |
Average Receivables |
6,436.50 | 7,325.50 | 6,475.00 | 5,749.00 | 5,128.50 | 4,555.00 | 4,112.50 | 3,552.00 | 3,233.50 | 3,384.00 |
Average Payables |
2,037.50 | 2,113.00 | 1,961.00 | 1,785.50 | 1,737.00 | 1,721.00 | 1,786.50 | 2,244.50 | 2,402.50 | 2,367.00 |
Average Inventory |
4,460.00 | 4,939.00 | 4,827.50 | 4,576.50 | 4,412.50 | 4,110.50 | 3,825.50 | 3,927.00 | 3,514.00 | 3,093.00 |
Average Assets |
73,645.00 | 81,836.00 | 65,649.00 | 59,076.50 | 54,055.00 | 49,153.00 | 45,838.50 | 43,745.00 | 41,402.50 | 40,037.00 |
Average Common Equity |
29,004.50 | 23,243.50 | 15,454.00 | 15,428.50 | 13,062.50 | 11,153.00 | 9,921.00 | 8,361.50 | 6,752.50 | 6,647.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026